[Treatment with antiangiogenic drugs]

Area of Science:

• Oncology
• Medical Research

Background:

• Antiangiogenesis therapy targets tumor blood vessel formation.
• Bevacizumab is a monoclonal antibody inhibiting vascular endothelial growth factor (VEGF).

Purpose of the Study:

• To evaluate the efficacy and limitations of bevacizumab in cancer treatment.
• To compare bevacizumab with small molecule VEGF inhibitors.

Main Methods:

• Review of clinical trial data for bevacizumab in various cancers.
• Analysis of adverse events and cost-effectiveness.

Main Results:

• Bevacizumab improved response rates, progression-free survival, and overall survival in colon, breast, lung, and renal cancers.
• It potentiates the antitumor activity of cytotoxic drugs.
• High cost and adverse events (hypertension, bleeding) are noted limitations.
• Small molecule VEGF inhibitors showed limited survival benefits except in renal and hepatic cancers.

Conclusions:

• Bevacizumab is an effective antiangiogenesis agent, enhancing chemotherapy.
• Cost and adverse events necessitate careful patient selection and monitoring.
• Further research into more cost-effective and safer antiangiogenesis strategies is warranted.